daraxonrasib

London, August 10, 2026 Silence Therapeutics plc announced positive topline results from the Phase 2 SANRECO trial of divesiran...

San Carlos, Calif. & Redwood City, Calif., August 10, 2026 BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a...

MADISON, Wis. – July 24, 2026 Elephas Biosciences Corporation has unveiled new preclinical data demonstrating that its elive™ functional...

Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...

REDWOOD CITY, Calif., July 7, 2026 Revolution Medicines has announced a major regulatory milestone as the European Medicines Agency...

REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...

REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...

MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...

PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...

REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...